Targeting HIF2α in Clear-Cell Renal Cell Carcinoma
- PMID: 27728802
- DOI: 10.1016/j.ccell.2016.09.016
Targeting HIF2α in Clear-Cell Renal Cell Carcinoma
Abstract
In two recent studies, the HIF2α antagonist, PT2399, decreased HIF2α-dependent transcription and tumor growth in selected VHL-deficient clear-cell renal cell carcinoma (ccRCC) models. These studies validate HIF2α as a therapeutic target in ccRCC, reveal variable sensitivity to HIF2α antagonism, and provide the foundation for predictive biomarker-driven clinical trials.
Published by Elsevier Inc.
Comment on
-
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.Nature. 2016 Nov 3;539(7627):107-111. doi: 10.1038/nature19795. Epub 2016 Sep 5. Nature. 2016. PMID: 27595393 Free PMC article.
-
Targeting renal cell carcinoma with a HIF-2 antagonist.Nature. 2016 Nov 3;539(7627):112-117. doi: 10.1038/nature19796. Epub 2016 Sep 5. Nature. 2016. PMID: 27595394 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical